The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: Who benefits themost?

European Heart Journal

Volumn 36, Issue 26, 2015, Pages 1676-1688

  Raphael, Claire E ^a   Finegold, Judith A ^a   Barron, Anthony J ^a   Whinnett, Zachary I ^a   Mayet, Jamil ^a   Linde, Cecilia ^b   Cleland, John G F ^c   Levy, Wayne C ^d   Francis, Darrel P ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; ICD; Implantable cardioverter defibrillator; Lifespan; Mortality; Sudden death

Indexed keywords

AGING; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; COMORBIDITY; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LIFESPAN; LIFESPAN GAIN; LOW RISK PATIENT; PACEMAKER IMPLANTATION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SECONDARY PREVENTION; SUDDEN CARDIAC DEATH; SURVIVAL; SYSTEMATIC REVIEW; AGED; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; EPIDEMIOLOGY; HEART LEFT VENTRICLE FUNCTION; HEART PACING; LONGEVITY; MIDDLE AGED; MORTALITY;

AGED; ARRHYTHMIAS, CARDIAC; CARDIAC PACING, ARTIFICIAL; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; EPIDEMIOLOGIC METHODS; HEART FAILURE; HUMANS; LONGEVITY; MIDDLE AGED; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84942432366     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv102     Document Type: Article

References (40)

1. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl J Med 1997; 337:1576-1583.
2. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237.
3. Moss AJ, ZarebaW, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, BrownMW, Andrews ML, Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The multi-centre automated defibrillator implantation trial II (MADIT II) investigators. N Engl J Med 2002;346:877-883.
4. Al-Khatib SM, Hellkamp AS, Hernandez AF, Fonarow GC, Thomas KL, Al-Khalidi HR, Heidenreich P, Hammill S, Yancy C, Peterson ED. Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time? Circulation 2012;125:1094-1101.
5. Hess PL, Grau-SepulvedaMV, Hernandez AF, Peterson ED, Bhatt DL, Schwamm LH, Yancy CW, Fonarow GC, Al-Khatib SM. Age differences in the use of implantable cardioverter-defibrillatorsamong older patients hospitalized with heart failure. J Cardiovasc Electrophysiol 2013;24:664-671.
6. Al-Khatib SM, Hellkamp A, Curtis J, Mark D, Peterson E, Sanders GD, Heidenreich PA, Hernandez AF, Curtis LH, Hammill S. Non-evidence-based ICD implantations in the United States. JAMA 2011;305:43-49.
7. Grady D. Many defibrillators implanted unnecessarily, study says. New York Times.2011 January 5:A12.
8. Tracy CM, Epstein AE, Darbar D, Dimarco JP, Dunbar SB, Estes NA III, Ferguson TB Jr, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ, Silka MJ, Stevenson LW, Stevenson WG, Varosy PD. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:1297-1313.
9. Thibodeau JB, Pillarisetti J, Khumri TM, Jones PG, Main ML. Mortality rates and clinical predictors of reduced survival after cardioverter defibrillator implantation. Am J Cardiol 2008;101:861-864.
10. Hess PL, Grau-SepulvedaMV, Hernandez AF, Peterson ED, Bhatt DL, Schwamm LH, Yancy CW, Fonarow GC, Al-Khatib SM; for the Get with The Guidelines Steering Committee and Hospitals. Age differences in the use of implantable cardioverterdefibrillators among older patients hospitalized with heart failure. J Cardiovasc Electrophysiol 2013;24:664-671.
11. Makeham WM. On the law of mortality and the construction of annuity tables. J Inst Actuaries Assur Mag 1860;8:301-310.
12. Arias E. United States Life Tables, 2003. Natl Vital Stat Rep 2006;54:1-40.
13. Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JG, Carson PE, Maggioni AP, Mann DL, Pitt B, Poole-Wilson PA, Levy WC. Prediction of mode of death in heart failure: The SeattleHeart Failure Model. Circulation 2007;116:392-398.
14. Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT, Maggioni AP, Anand I, Poole-Wilson PA, Fishbein DP, Johnson G, Anderson J, Mark DB, Bardy GH. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009; 120:835-842.
15. Wever EF, Hauer RN, Schrijvers G, van Capelle FJ, Tijssen JG, Crijns HJ, Algra A, Ramanna H, Bakker PF, Robles de Medina EO. Randomised study of implantable defibrillators as first-choice therapy versus conventional strategy in post-infarct sudden death survivors. Circulation 1995;91:2195-2203.
16. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ, O'Brien B. Canadian implantable defibrillator study (CIDS). A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-1302.
17. Kuck K-H, Cappato R, Siebels J, Rüppel R. Randomised comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The cardiac arrest study Hamberg (CASH). Circulation 2000;102: 748-754.
18. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implantable defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. The multi-centre automated defibrillator implantation trial (MADIT) investigators. N Engl J Med 1996;335:1933-1940.
19. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. The multi-center unsustained tachycardia trial (MUSTT) investigators. N Engl J Med 1999;341:1882-1890.
20. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, Bitar C, Morady F; AMIOVIRT Investigators. Amiodarone versus implantable cardioverterdefibrillator: Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 2003;41:1707-1712.
21. Bänsch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, Block M, Gietzen F, Berger J, Kuck KH. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: The Cardiomyopathy Trial (CAT). Circulation 2002;105: 1453-1458.
22. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH, Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-2158.
23. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, Kornacewicz-Jach Z, Sredniawa B, Lupkovics G, Hofgärtner F, Lubinski A, Rosenqvist M, Habets A, Wegscheider K, Senges J, IRIS Investigators. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009;361:1427-1436.
24. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481-2488.
25. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. The multi-center unsustained tachycardia trial (MUSTT) investigators. N Engl J Med 1999;341:1882-1890.
26. Mark DB, Nelson CL, Anstrom KJ, Al-Khatib SM, Tsiatis AA, Cowper PA, Clapp-Channing NE, Davidson-Ray L, Poole JE, Johnson G, Anderson J, Lee KL, Bardy GH; SCD-HeFT Investigators. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006;114:135-142.
27. Zwanziger J, Hall WJ, Dick AW, Zhao H, Mushlin AI, Hahn RM, Wang H, Andrews ML, Mooney C, Wang H, Moss AJ. The cost effectiveness of implantable cardioverter-defibrillators: Results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006;47:2310-2318.
28. Levy WC, Mozaffarian D, Linker DT, Kenyon KW, Cleland JG, Komajda M, Remme WJ, Torp-Pedersen C, Metra M, Poole-Wilson PA; COMET Investigators. Years-needed-to-treat to add 1 year of life: A new metric to estimate treatment effects in randomized trials. Eur J Heart Fail 2009;11:256-263.
29. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior appropriate implantable cardioverter-defibrillator therapy: A competing risk study. Circulation 2008;117:1918-1926.
30. Clarke B, Howlett J, Sapp J, Andreou P, Parkash R. The effect of comorbidity on the competing risk of sudden and non sudden death in an ambulatory heart failure population. Can J Cardiol 2011;27:254-261.
31. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, Smith AL, Agha SA, Waheed S, Laskar S, Puskas J, Dunbar S, Vega D, Levy WC, Butler J. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J Am Coll Cardiol 2009;53:334-342.
32. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
33. Moss AJ, Schuger C, Beck CA, BrownMW, Cannom DS, Daubert JP, Estes NA 3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W; MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367:2275-2283.
34. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, Sharma A; Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dualchamber pacing or ventricular backup pacing in patients with an implantable defibrillator: The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002;288:3115-3123.
35. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE; ESCCommittee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bänsch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D, Faerestrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM. 2013 ESCGuidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013;34:2281-2329.
36. SalukheTV, Briceno NI, Ferenczi EA, Sutton R, FrancisDP. Is there benefit in implanting defibrillators in patients with severe heart failure? Heart 2010;96:599-603.
37. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the 'DEALE'). Am J Med 1982;73:883-888.
38. Schowalter M, Gelbrich G, Stö rk S, Langguth JP, Morbach C, Ertl G, Faller H, Angermann CE. Generic and disease-specific health-related quality of life in patients with chronic systolic heart failure: impact of depression. Clin Res Cardiol 2013;102: 269-278.
39. Borne RT, Peterson PN, Greenlee R, Heidenreich PA, Wang Y, Curtis JP, Tzou WS, Varosy PD, Kremers MS, Masoudi FA. Temporal trends in patient characteristics and outcomes among Medicare beneficiaries undergoing primary prevention implantable cardioverter-defibrillator placement in the United States, 2006-2010. Results from the National Cardiovascular Data Registry's Implantable Cardioverter- Defibrillator Registry. Circulation 2014;130:845-853.
40. Krahn AD, Lee DS, Birnie D, Healey JS, Crystal E, Dorian P, Simpson CS, Khaykin Y, Cameron D, Janmohamed A, Yee R, Austin PC, Chen Z, Hardy J, Tu JV; Ontario ICD Database Investigators. Predictors of short-term complications after implantable cardioverter-defibrillator replacement: Results from the Ontario ICD Database. Circ Arrhythm Electrophysiol 2011;4:136-142.